Vertex Expands Beyond Cystic Fibrosis | Business and Finance News

Vertex Pharmaceuticals is weathering investor concerns about competition in cystic fibrosis, as rivals like Sionna and Krystal Biotech push their own drugs — though Sionna’s latest candidate recently failed. Yet Vertex isn’t resting: it’s aggressively expanding beyond CF, targeting $500M in non-CF revenue by 2026. Key bets include gene-editing therapy Casgevy (now approved for kids as young as two), the painkiller Journavx, and povetacicept — a kidney disease treatment poised for approval by November with potential to hit $1B annually. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2b55f87e8fbb79be